Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.58
BICX's Cash-to-Debt is ranked higher than
64% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. BICX: 0.58 )
Ranked among companies with meaningful Cash-to-Debt only.
BICX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.12 Max: No Debt
Current: 0.58
Equity-to-Asset -1.35
BICX's Equity-to-Asset is ranked lower than
100% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. BICX: -1.35 )
Ranked among companies with meaningful Equity-to-Asset only.
BICX' s Equity-to-Asset Range Over the Past 10 Years
Min: -21.29  Med: 0.05 Max: 0.99
Current: -1.35
-21.29
0.99
Debt-to-Equity -0.86
BICX's Debt-to-Equity is ranked lower than
99.99% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 0.57 vs. BICX: -0.86 )
Ranked among companies with meaningful Debt-to-Equity only.
BICX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.67  Med: 0 Max: 5.06
Current: -0.86
-1.67
5.06
Piotroski F-Score: 3
Altman Z-Score: -100.87
Beneish M-Score: -42.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -418.76
BICX's Operating Margin % is ranked lower than
98% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. BICX: -418.76 )
Ranked among companies with meaningful Operating Margin % only.
BICX' s Operating Margin % Range Over the Past 10 Years
Min: -553.3  Med: -260.72 Max: -44.56
Current: -418.76
-553.3
-44.56
Net Margin % -4981.56
BICX's Net Margin % is ranked lower than
100% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. BICX: -4981.56 )
Ranked among companies with meaningful Net Margin % only.
BICX' s Net Margin % Range Over the Past 10 Years
Min: -4981.56  Med: -267.12 Max: -52.98
Current: -4981.56
-4981.56
-52.98
ROA % -2607.69
BICX's ROA % is ranked lower than
100% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. BICX: -2607.69 )
Ranked among companies with meaningful ROA % only.
BICX' s ROA % Range Over the Past 10 Years
Min: -2607.69  Med: -166.67 Max: -18.07
Current: -2607.69
-2607.69
-18.07
ROC (Joel Greenblatt) % -12786.41
BICX's ROC (Joel Greenblatt) % is ranked lower than
100% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 16.07 vs. BICX: -12786.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BICX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -102360  Med: -16784.62 Max: -6254.55
Current: -12786.41
-102360
-6254.55
3-Year Revenue Growth Rate -12.60
BICX's 3-Year Revenue Growth Rate is ranked lower than
91% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. BICX: -12.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BICX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.75 Max: 14.5
Current: -12.6
0
14.5
3-Year EBITDA Growth Rate -13.40
BICX's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. BICX: -13.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BICX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.4 Max: 74.7
Current: -13.4
0
74.7
GuruFocus has detected 5 Warning Signs with BioCorRx Inc $BICX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BICX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BICX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621498    SIC: 8093
Compare:OTCPK:MIHI, TSXV:CXV, AMEX:AMS, OTCPK:HPHW, AMEX:SSY, OTCPK:PFHO, OTCPK:FCHS, OTCPK:BDMS, OTCPK:WNDM, OTCPK:SPIN, OTCPK:LMNK, TSXV:AHI, OTCPK:USNU, OTCPK:CCEL, NAS:JYNT, OTCPK:AMEH, NAS:CATS, TSXV:IOM, AMEX:HLTH, OTCPK:NVOS » details
Headquarter Location:USA
BioCorRx Inc is an alcohol treatment and rehabilitation company. The Company is engaged in the development of BioCorRx Recovery Program for the treatment of alcoholism and opioid addiction consisting of a naltrexone implant.

BioCorRx Inc is an alcohol treatment and rehabilitation company. The Company is engaged in the development of BioCorRx Recovery Program for the treatment of alcoholism and opioid addiction consisting of a naltrexone implant.

Top Ranked Articles about BioCorRx Inc

US Prisons Relying on Naltrexone to Treat Opioid Addiction 'Anything we can do is positive'
More U.S. prisons are relying on naltrexone as an effective method in treating inmates with opioid addiction. Jail and prison systems in 28 states across the nation are using naltrexone under the brand name Vivitrol, for their anti-drug addiction program. Read more...
Private Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx Alpine Creek has completed its equity financing of addiction treatment company offering a unique approach to the treatment of substance abuse addiction
Private equity firm Alpine Creek has completed its equity financing of BioCorRx Inc. (BICX), an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. Read more...
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/3-24-17-smallcapvoice-interview-with-biocorrx-inc-bicx.
Brady Granier and Lourdes Felix called in to SmallCapVoice.com, Inc. to go over the exciting recent news for the Company. BICX recently announced it moved up to the OTCQB, their upcoming presentation at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29th, the positive preliminary data from preclinical studies evaluating BICX101, the validating work BICX is doing with the City of Anaheim to treat opioid and alcohol addiction, and more. "We are very happy with the way things are progressing with the company’s initiatives," stated Granier.  "This interview restates some of our most recent developments and we look forward to providing more updates in the future." About SmallCapVoice.com SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for their ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/.   About BioCorRx BioCorRx Inc. (BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com. Safe Harbor Statement The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
[email protected]
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304 
[email protected]

For SmallCapVoice.com
Stuart T. Smith
512-267-2430 
[email protected]

Read more...
Majority of US Employers: Prescription Drug Misuse Is Grounds for Termination Workplace can play a key role in helping addicted employees
DISCLOSURE: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I am receiving compensation for the article. Read more...
America’s War on Drugs 'Forgotten people' are at greatest risk
President Donald Trump described them as America’s “forgotten people,” the less-educated white, middle-aged Americans. This group of individuals, together with the baby boomers and the so-called Generation X, are among the most vulnerable to heroin and prescription drug abuse. Several studies indicate that the number of drug overdose deaths among baby boomers, Generation X and less-educated white Americans has jumped in recent years. Read more...
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...

Ratios

vs
industry
vs
history
PS Ratio 26.67
BICX's PS Ratio is ranked lower than
99% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. BICX: 26.67 )
Ranked among companies with meaningful PS Ratio only.
BICX' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 7.39 Max: 370
Current: 26.67
1
370
EV-to-EBIT -7.75
BICX's EV-to-EBIT is ranked lower than
99.99% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 20.05 vs. BICX: -7.75 )
Ranked among companies with meaningful EV-to-EBIT only.
BICX' s EV-to-EBIT Range Over the Past 10 Years
Min: -366.8  Med: -6.6 Max: -0.7
Current: -7.75
-366.8
-0.7
EV-to-EBITDA -7.89
BICX's EV-to-EBITDA is ranked lower than
99.99% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 15.41 vs. BICX: -7.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
BICX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -366.8  Med: -7 Max: -0.7
Current: -7.89
-366.8
-0.7
EV-to-Revenue 32.45
BICX's EV-to-Revenue is ranked lower than
99% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. BICX: 32.45 )
Ranked among companies with meaningful EV-to-Revenue only.
BICX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 7.8 Max: 389.8
Current: 32.45
1.4
389.8
Current Ratio 0.82
BICX's Current Ratio is ranked lower than
59% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. BICX: 0.82 )
Ranked among companies with meaningful Current Ratio only.
BICX' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.52 Max: 5.44
Current: 0.82
0.04
5.44
Quick Ratio 0.82
BICX's Quick Ratio is ranked lower than
55% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. BICX: 0.82 )
Ranked among companies with meaningful Quick Ratio only.
BICX' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.52 Max: 5.44
Current: 0.82
0.04
5.44
Days Sales Outstanding 30.17
BICX's Days Sales Outstanding is ranked higher than
87% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. BICX: 30.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
BICX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.05  Med: 160.29 Max: 452.04
Current: 30.17
11.05
452.04
Days Payable 347.99
BICX's Days Payable is ranked lower than
99.99% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 44.51 vs. BICX: 347.99 )
Ranked among companies with meaningful Days Payable only.
BICX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 347.99
Current: 347.99
0
347.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.60
BICX's 3-Year Average Share Buyback Ratio is ranked lower than
75% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. BICX: -12.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BICX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19  Med: -9.95 Max: 39.3
Current: -12.6
-19
39.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 4.00
BICX's Price-to-Median-PS-Value is ranked lower than
97% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. BICX: 4.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BICX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1 Max: 15
Current: 4
0.14
15
Earnings Yield (Greenblatt) % -12.90
BICX's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.84 vs. BICX: -12.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BICX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -136.5  Med: -15.2 Max: -0.3
Current: -12.9
-136.5
-0.3

More Statistics

Revenue (TTM) (Mil) $0.63
EPS (TTM) $ -0.19
Beta0.82
Short Percentage of Float0.00%
52-Week Range $0.01 - 0.34
Shares Outstanding (Mil)242.14

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}